Foundation Medicine Awarded Genomic Profiling Contract by the United States Department of Veterans Affairs
Veterans with Advanced Cancer to Have Better Access to Foundation Medicine’s Comprehensive Genomic Profiling Tests to Help Inform Personalized Treatment Plans
CAMBRIDGE, Mass. -- February 5, 2019 -- Foundation Medicine, Inc. today announced a nationwide contract with the U.S. Department of Veterans Affairs National Precision Oncology Program to provide comprehensive genomic profiling (CGP) for eligible Veterans living with advanced cancer. The contract covers all of Foundation Medicine’s available tests including FoundationOne®CDx and FoundationOne®Liquid for solid tumors as well as FoundationOne®Heme for hematologic malignancies. The company’s portfolio of CGP tests provides information about clinically relevant genomic alterations to help match patients to targeted therapies, immunotherapies and clinical trials.
“Foundation Medicine is honored to be awarded a contract by the U.S. Department of Veterans Affairs to provide comprehensive genomic profiling for Veterans with advanced cancer,” said Cindy Perettie, Chief Executive Officer at Foundation Medicine. “Our tests are critical to determining the genomic drivers of cancer and what makes each patient’s disease unique, to enable a personalized treatment approach. It is imperative that every advanced cancer patient has access to this information and we are privileged to provide our tests to the people who served our country. This decision by the VA as well as Medicare’s National Coverage Determination issued in early 2018, mark important steps forward in access to personalized cancer care.”
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.
Lee-Ann Murphy, 617-245-3077